Trends in antidepressant utilization from 2001 to 2004

Psychiatric Services

Volumn 60, Issue 5, 2009, Pages 611-616

  Harman, Jeffrey S ^a,b   Edlund, Mark J ^b   Fortney, John C ^c  

^a Department of Health Services Research Management and Policy   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; AGED; ANXIETY DISORDER; ARTICLE; COMORBIDITY; DEPRESSION; DRUG USE; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; SELF REPORT;

EID: 66249123109     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2009.60.5.611     Document Type: Article

References (23)

1. Pincus HA, Tanielian TL, Marcus SC, et al: Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 279:526-531, 1998
2. Olfson M, Marcus SC, Druss B, et al: National trends in the outpatient treatment of depression. JAMA 287:203-209, 2002
3. Harman JS, Crystal S, Walkup J, et al: Trends in elderly patients' office visits for the treatment of depression according to physician specialty: 1985-1999. Journal of Behavioral Health Services and Research 30:332-341, 2003
4. Harman JS, Mulsant B, Kelleher KJ, et al: Narrowing the gap in treatment of depression. International Journal of Psychiatry in Medicine 31:255-269, 2001
5. Wang PS, Demler O, Olfson M, et al: Changing profiles of service sectors used for mental health care in the United States. American Journal of Psychiatry 163:1187-1198, 2006
6. Nemeroff CB, Kalali A, Keller MB, et al: Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of General Psychiatry 64:466-472, 2007
7. Olfson M, Marcus SC, Druss BG: Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Archives of General Psychiatry 65:94-101, 2008
8. Gibbons RD, Brown CH, Hur K, et al: Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164:1356-1363, 2007
9. Libby AM, Brent DA, Morrato EH, et al: Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Psychiatry 164:884-891, 2007
10. Cheung A, Sacks D, Dewa CS, et al: Pediatric prescribing practices and the FDA black-box warning on antidepressants. Journal of Developmental and Behavioral Pediatrics 29:213-215, 2008
11. Morrato EH, Libby AM, Orton HD, et al: Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. American Journal of Psychiatry 165: 42-50, 2008
12. Valuck RJ, Libby AM, Orton HD, et al: Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. American Journal of Psychiatry 164:1198-1205, 2007
13. Cohen SB: Sample design of the 1996 Medical Expenditure Panel Survey Household Component. Rockville, Md, Agency for Healthcare Research and Quality, 1997
14. Weilburg JB, O'Leary KM, Meigs JB, et al: Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatric Services 54:1233-1239, 2003
15. Practice guidelines for major depressive disorder in adults: American Psychiatric Association. American Journal of Psychiatry 150(suppl 4):1-26, 1993
16. Depression Guideline Panel: Depression in Primary Care: Vol 1: Detection and Diagnosis. Pub no AHCPR 93-0550. Rockville, Md, Agency for Health Care Policy and Research, 1993
17. Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105, 2003
18. Harman JS, Edlund MJ, Fortney JC: Disparities in the adequacy of depression care in the United States. Psychiatric Services 55:1379-1385, 2004
19. Harman JS, Edlund MJ, Fortney JC, et al: The influence of comorbid chronic medical conditions on the adequacy of depression care for older Americans. Journal of the American Geriatrics Society 53:2178-2183, 2005
20. Stata Statistical Software: Release 8.0 Special Edition. College Station, Tex, Stata Corp, 2003
21. Young AS, Klap R, Sherbourne CD, et al: The quality of care for depressive and anxiety disorders in the United States. Archives of General Psychiatry 58:55-61, 2001
22. Jureidini J, Tonkin A: Overuse of antidepressant drugs for the treatment of depression. CNS Drugs 20:623-632, 2006
23. Katz SJ, Kessler RC, Lin E, et al: Medication management of depression in the United States and Ontario. Journal of General Internal Medicine 13:77-85, 1998